drugset
drugset / Trial / NCT05274659

A Study to Evaluate the Safety and Tolerability of KJ103 in Healthy Adults

NCT05274659 ↗

Phase 1 Completed 34 enrolled Shanghai Bao Pharmaceuticals Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a randomized, single-blinded, placebo controlled, single ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) and immunogenicity of KJ103 in healthy subjects.

Timeline

Start
2022-05-19
Primary completion
2023-03-18
Completion
2023-08-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator KJ103 Unknown — Intravenous

Indications

No indication recorded.